Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT06998108Phase 3Recruiting
- Sponsor
- BeBetter Med
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bebt-209 in breast cancer, sponsored by BeBetter Med. Started Jun 2022; status: recruiting.
02
Drugs
bebt-209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06998108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998108.